Cjm112

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Cjm112 is an investigational medication currently being studied by Novartis Pharmaceuticals. It is being evaluated in clinical trials, including one for colorectal cancer (CRC), often in combination with other experimental drugs. The goal of these early-phase trials (Phase 1) is primarily to assess the safety and tolerability of Cjm112, determine the best way to administer it, and look for early signs of effectiveness (antitumor activity). It is not yet approved for treating CRC or any other condition. The trials often include patients whose tumors express PD-L1.

Mechanism of Action

The specific way Cjm112 works (its mechanism of action) is still being investigated in clinical trials. It is being studied in combination with other agents like PDR001, EGF816, canakinumab, and trametinib to see if these combinations are safe and effective against certain cancers, including CRC. The drug targets proteins involved in tumor growth.

Side Effects

As Cjm112 is an investigational drug in early-phase trials The full range of potential side effects is still being evaluated. The primary focus of Phase 1 trials is safety So researchers carefully monitor participants for any adverse events. Specific side effects observed in the NCT02900664 trial involving Cjm112 in combination with other drugs are not detailed in the provided information But common side effects in early cancer drug trials can vary widely depending on the drug and the combination used.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02900664 Phase 1
Archived
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
United States, Belgium, Canada, France, Israel, Italy, Singapore, Spain, Taiwan

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.